Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management
EA Gorman, CM O'Kane, DF McAuley - The Lancet, 2022 - thelancet.com
Acute respiratory distress syndrome (ARDS) is characterised by acute hypoxaemic
respiratory failure with bilateral infiltrates on chest imaging, which is not fully explained by …
respiratory failure with bilateral infiltrates on chest imaging, which is not fully explained by …
COVID-19: Discovery, diagnostics and drug development
T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021 - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …
and has since become a pandemic. Groups from China identified and sequenced the virus …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …
F Ader, M Bouscambert-Duchamp, M Hites… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 …
L Russell, KR Uhre, ALS Lindgaard, JF Degn… - Jama, 2021 - jamanetwork.com
Importance A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in
patients with severe and critical COVID-19, but a higher dose may benefit those with more …
patients with severe and critical COVID-19, but a higher dose may benefit those with more …
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
Pathogenesis of pneumonia and acute lung injury
ME Long, RK Mallampalli, JC Horowitz - Clinical Science, 2022 - portlandpress.com
Pneumonia and its sequelae, acute lung injury, present unique challenges for pulmonary
and critical care healthcare professionals, and these challenges have recently garnered …
and critical care healthcare professionals, and these challenges have recently garnered …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
[PDF][PDF] Clinical management of COVID-19: interim guidance, 27 May 2020
(2020 World Health Organization - 2020 - apps.who.int
Methods The original version of this document was developed in consultation with the
International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory …
International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory …
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in …
P Toniati, S Piva, M Cattalini, E Garrafa, F Regola… - Autoimmunity …, 2020 - Elsevier
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress
syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 …
syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 …